Sodium Sulfate side effects: what 604 FDA adverse event reports show
Drug class
Not stated in label
Brand names
Natrum Sulphuricum
Who reports
604 reports · 59% serious · 38 with death outcome · 70% female
Used for
Bronchial irritation worsened by humidity
Boxed warning
None in the current label
Causality screen of the 6 strongest signals
What the badges mean
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
- No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 0 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Macular degeneration | 17 | 49.6 31.0–79.3ROR 51.0 · χ² 761 / p 9e-168 | 47.1 EB05 31.1 · IC025 +3.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 51.9 | no trial data cached |
| Vaginal discharge | 7 | 24.2 11.6–50.6ROR 24.5 · χ² 133 / p 4e-31 | 22.0 EB05 10.0 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=7 | no trial data cached |
| Paraesthesia oral | 9 | 21.8 11.4–41.6ROR 22.1 · χ² 158 / p 2e-36 | 20.3 EB05 10.5 · IC025 +2.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 37.7 | no trial data cached |
| Procedural pain | 10 | 12.6 6.8–23.2ROR 12.8 · χ² 95 / p 9e-23 | 10.5 EB05 5.3 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 21.0 | no trial data cached |
| Product substitution issue | 11 | 6.6 3.7–11.9ROR 6.7 · χ² 47 / p 3e-12 | 5.4 EB05 3.2 · IC025 +1.4 3/3 methods agree | Reporting / coding artifact | serious PRR 11.2 | no trial data cached |
| Multiple sclerosis relapse | 10 | 5.0 2.7–9.3ROR 5.1 · χ² 28 / p 5e-8 | 4.2 EB05 2.4 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.4 | no trial data cached |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Macular degeneration | 17 | 49.6 31.0–79.3ROR 51.0 · χ² 761 / p 9e-168 | 47.1 EB05 31.1 · IC025 +3.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 51.9 | no trial data cached |
| Product substitution issue | 11 | 6.6 3.7–11.9ROR 6.7 · χ² 47 / p 3e-12 | 5.4 EB05 3.2 · IC025 +1.4 3/3 methods agree | Reporting / coding artifact | serious PRR 11.2 | no trial data cached |
| Multiple sclerosis relapse | 10 | 5.0 2.7–9.3ROR 5.1 · χ² 28 / p 5e-8 | 4.2 EB05 2.4 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.4 | no trial data cached |
| Procedural pain | 10 | 12.6 6.8–23.2ROR 12.8 · χ² 95 / p 9e-23 | 10.5 EB05 5.3 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 21.0 | no trial data cached |
| Paraesthesia oral | 9 | 21.8 11.4–41.6ROR 22.1 · χ² 158 / p 2e-36 | 20.3 EB05 10.5 · IC025 +2.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 37.7 | no trial data cached |
| Vaginal discharge | 7 | 24.2 11.6–50.6ROR 24.5 · χ² 133 / p 4e-31 | 22.0 EB05 10.0 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=7 | no trial data cached |
Unlabeled candidate signals
Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Sodium Sulfate?
In FDA FAERS, the most frequently co-reported reaction terms for Sodium Sulfate are macular degeneration, multiple sclerosis relapse, procedural pain, paraesthesia oral, vaginal discharge. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Sodium Sulfate have an FDA boxed warning?
No. The FDA label retrieved for Sodium Sulfate has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Sodium Sulfate causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 86475307-ddef-1f41-e053-2991aa0a11f1, effective 20230106; matched on
openfda.generic_name.exact:"SODIUM SULFATE") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 6 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.